Radiopharmaceutical company Clarity Pharmaceuticals and the University of Melbourne have been awarded an Australian Research Council (ARC) Linkage grant to fund the development of new agents for diagnostic imaging using positron emission tomography (PET). The ultimate aim of the project is to try to improve molecular imaging of the brain for various disorders.
Valued at $365,000 over three years, the grant will fund research into the use of PET isotopes of copper, gallium and fluorine with a view to replacing existing technologies that rely on single-photon emission from technetium and the technique of single photon emission computed tomography. It has been co-awarded to the University of Melbourne’s Associate Professor Paul Donnelly, the inventor of several patents for radiopharmaceutical technologies. Read more.